nach oben

Erschienen in:

04.01.2022 | Original Article

Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985–2016

verfasst von: Satoshi Miyamoto, Katsutsugu Umeda, Mio Kurata, Masakatsu Yanagimachi, Akihiro Iguchi, Yoji Sasahara, Keiko Okada, Takashi Koike, Reo Tanoshima, Masataka Ishimura, Masafumi Yamada, Maho Sato, Yoshiyuki Takahashi, Michiko Kajiwara, Hiroshi Kawaguchi, Masami Inoue, Yoshiko Hashii, Hiromasa Yabe, Koji Kato, Yoshiko Atsuta, Kohsuke Imai, Tomohiro Morio

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hematopoietic cell transplantation (HCT) is a curative therapy for most patients with inborn errors of immunity (IEI). We conducted a nationwide study on HCT for patients with IEI other than severe combined immunodeficiency (non-SCID) in Japan.

Methods

Data from the Japanese national database (Transplant Registry Unified Management Program, TRUMP) for 566 patients with non-SCID IEI, who underwent their first HCT between 1985 and 2016, were retrospectively analyzed.

Results

The 10-year overall survival (OS) and event-free survival (EFS) were 74% and 64%, respectively. The 10-year OS for HCT from unrelated bone marrow (URBM), accounting for 39% of HCTs, was comparable to that for HCT from matched sibling donor (MSD), 79% and 81%, respectively. HCT from unrelated cord blood (URCB), accounting for 28% of HCTs, was also common, with a 10-year OS of 69% but less robust engraftment. The intensity of conditioning was not associated with OS or neutrophil recovery; however, myeloablative conditioning was more frequently associated with infection-related death. Patients who received myeloablative irradiation showed poor OS. Multivariate analyses revealed that HCT in 1985–1995 (hazard ratio [HR], 2.0; P = 0.03), URCB (HR, 2.0; P = 0.01), and related donor other than MSD (ORD) (HR, 2.9; P < 0.001) were associated with poor OS, and URCB (HR, 3.6; P < 0.001) and ORD (HR, 2.7; P = 0.02) showed a higher incidence of retransplantation.

Conclusions

We present the 1985–2016 status of HCT for non-SCID IEI in Japan with sufficient statistical power, highlighting the potential of URBM as an alternative donor and the feasibility of reduced intensity conditioning.

Nur mit Berechtigung zugänglich

Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40:24–64. https://doi.org/10.1007/s10875-019-00737-x.CrossRefPubMedPubMedCentral

Zhang Q, Frange P, Blanche S, Casanova JL. Pathogenesis of infections in HIV-infected individuals: insights from primary immunodeficiencies. Curr Opin Immunol. 2017;48:122–33. https://doi.org/10.1016/j.coi.2017.09.002.CrossRefPubMedPubMedCentral

Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2:1366–9. https://doi.org/10.1016/s0140-6736(68)92673-1.CrossRefPubMed

Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2019. The Japanese Data Center for Hematopoietic Cell Transplantation/The Japan Society for Hematopoietic Cell Transplantation. Available at: http://www.jdchct.or.jp/data/report/2019/2-10-2.pdf. Accessed 23 Dec 2020.

Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol. 2011;154:363–72. https://doi.org/10.1111/j.1365-2141.2011.08735.x.CrossRefPubMed

Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74. https://doi.org/10.1532/IJH97.06239.CrossRefPubMed

Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38:129–43. https://doi.org/10.1007/s10875-017-0465-8.CrossRefPubMed

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.CrossRefPubMedPubMedCentral

Pai S-Y, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371:434–46. https://doi.org/10.1056/NEJMoa1401177.CrossRefPubMedPubMedCentral

10.

Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, et al. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018;132:1737–49. https://doi.org/10.1182/blood-2018-03-840702.CrossRefPubMedPubMedCentral

11.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.CrossRefPubMed

12.

Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10. https://doi.org/10.1016/j.jaci.2010.06.015.CrossRefPubMed

13.

Mitchell R, Nivison-Smith I, Anazodo A, Tiedemann K, Shaw P, Teague L, et al. Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Biol Blood Marrow Transplant. 2013;19:338–43. https://doi.org/10.1016/j.bbmt.2012.11.619.CrossRefPubMed

14.

Fernandes JF, Nichele S, Daudt LE, Tavares RB, Seber A, Kerbauy FR, et al. Transplantation of hematopoietic stem cells for primary immunodeficiencies in Brazil: challenges in treating rare diseases in developing countries. J Clin Immunol. 2018;38:917–26. https://doi.org/10.1007/s10875-018-0564-1.CrossRefPubMed

15.

Olaya M, Franco A, Chaparro M, Estupiñan M, Aristizabal D, Builes-Restrepo N, et al. Hematopoietic stem cell transplantation in children with inborn errors of immunity: a multi-center experience in Colombia. J Clin Immunol. 2020;40:1116–23. https://doi.org/10.1007/s10875-020-00856-w.CrossRefPubMed

16.

Miyamoto S, Umeda K, Kurata M, Nishimura A, Yanagimachi M, Ishimura M, et al. Hematopoietic cell transplantation for severe combined immunodeficiency patients: A Japanese retrospective study. J Clin Immunol. 2021. https://doi.org/10.1007/s10875-021-01112-5.CrossRefPubMedPubMedCentral

17.

Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60. https://doi.org/10.1016/S1470-2045(10)70127-3.CrossRefPubMedPubMedCentral

18.

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang M-J, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75. https://doi.org/10.1056/NEJMoa041276.CrossRefPubMed

19.

Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2011;17:78–85. https://doi.org/10.1016/j.bbmt.2010.06.011.CrossRefPubMed

20.

Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85. https://doi.org/10.1056/NEJMoa041469.CrossRefPubMed

21.

Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17:1375–82. https://doi.org/10.1016/j.bbmt.2011.01.012.CrossRefPubMedPubMedCentral

22.

Kurzay M, Hauck F, Schmid I, Wiebking V, Eichinger A, Jung E, et al. T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. Haematologica. 2019;104:e478–82. https://doi.org/10.3324/haematol.2018.215285.CrossRefPubMedPubMedCentral

23.

Neven B, Diana J-S, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019;25:1363–73. https://doi.org/10.1016/j.bbmt.2019.03.009.CrossRefPubMed

24.

Uppuluri R, Sivasankaran M, Patel S, Swaminathan VV, Ramanan KM, Ravichandran N, et al. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: Challenges and outcome from a tertiary care center in South India. J Clin Immunol. 2019;39:182–7. https://doi.org/10.1007/s10875-019-00600-z.CrossRefPubMedPubMedCentral

25.

Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21:1955–62. https://doi.org/10.1016/j.bbmt.2015.07.008.CrossRefPubMed

26.

Elfeky R, Shah RM, Unni MNM, Ottaviano G, Rao K, Chiesa R, et al. New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. J Allergy Clin Immunol. 2019;144:280–93. https://doi.org/10.1016/j.jaci.2019.01.030.CrossRefPubMed

27.

Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor αβ+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141:1417–26. https://doi.org/10.1016/j.jaci.2017.07.008.CrossRefPubMed

28.

Osumi T, Yoshimura S, Sako M, Uchiyama T, Ishikawa T, Kawai T, et al. Prospective study of allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and antithymocyte globulin from HLA-mismatched related donors for nonmalignant diseases. Biol Blood Marrow Transplant. 2020;26:e286–91. https://doi.org/10.1016/j.bbmt.2020.08.008.CrossRefPubMed

29.

Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med. 2020;217: e20190607. https://doi.org/10.1084/jem.20190607.CrossRefPubMed

30.

Horne A, Janka G, Maarten Egeler R, Gadner H, Imashuku S, Ladisch S, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129:622–30. https://doi.org/10.1111/j.1365-2141.2005.05501.x.CrossRefPubMed

31.

Ouachée-Chardin M, Elie C, de Saint BG, Le Deist F, Mahlaoui N, Picard C, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117:e743–50. https://doi.org/10.1542/peds.2005-1789.CrossRefPubMed

32.

Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382:1811–22. https://doi.org/10.1056/NEJMoa1911326.CrossRefPubMed

33.

Ramanan KM, Uppuluri R, Ravichandran N, Patel S, Swaminathan VV, Jayakumar I, et al. Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67: e28071. https://doi.org/10.1002/pbc.28071.CrossRefPubMed

34.

Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142:1665–9. https://doi.org/10.1016/j.jaci.2018.07.020.CrossRefPubMedPubMedCentral

35.

Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142:1932–46. https://doi.org/10.1016/j.jaci.2018.02.055.CrossRefPubMedPubMedCentral

36.

Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349:436–40. https://doi.org/10.1126/science.aaa1663.CrossRefPubMed

37.

Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017;130:2307–16. https://doi.org/10.1182/blood-2017-08-801191.CrossRefPubMedPubMedCentral

38.

Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020;135:2094–105. https://doi.org/10.1182/blood.2019002939.CrossRefPubMedPubMedCentral

39.

Shekhovtsova Z, Bonfim C, Ruggeri A, Nichele S, Page K, AlSeraihy A, et al. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. Haematologica. 2017;102:1112–9. https://doi.org/10.3324/haematol.2016.158808.CrossRefPubMedPubMedCentral

40.

Furtado-Silva JM, Paviglianiti A, Ruggeri A, Boelens JJ, Veys P, Ahmari AA, et al. Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2019;184:397–404. https://doi.org/10.1111/bjh.15642.CrossRefPubMed

41.

Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54:299–306. https://doi.org/10.1002/pbc.22310.CrossRefPubMed

42.

Yanagimachi M, Kato K, Iguchi A, Sasaki K, Kiyotani C, Koh K, et al. Hematopoietic cell transplantation for chronic granulomatous disease in Japan. Front Immunol. 2020;11:1617. https://doi.org/10.3389/fimmu.2020.01617.CrossRefPubMedPubMedCentral

43.

Chiesa R, Wang J, Blok H-J, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136:1201–11. https://doi.org/10.1182/blood.2020005590.CrossRefPubMed

44.

Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436–48. https://doi.org/10.1016/S0140-6736(13)62069-3.CrossRefPubMed

45.

Osumi T, Tomizawa D, Kawai T, Sako M, Inoue E, Takimoto T, et al. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. 2019;54:168–72. https://doi.org/10.1038/s41409-018-0271-9.CrossRefPubMed

46.

Iguchi A, Cho Y, Yabe H, Kato S, Kato K, Hara J, et al. Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey. Int J Hematol. 2019;110:364–9. https://doi.org/10.1007/s12185-019-02686-y.CrossRefPubMed

47.

Umeda K, Adachi S, Horikoshi Y, Imai K, Terui K, Endo M, et al. Allogeneic hematopoietic stem cell transplantation for Chediak-Higashi syndrome. Pediatr Transplant. 2016;20:271–5. https://doi.org/10.1111/petr.12626.CrossRefPubMed

48.

Burrows PD, Fischer A. Building networks for immunodeficiency diseases and immunology training. Nat Immunol. 2008;9:1005–7. https://doi.org/10.1038/ni0908-1005.CrossRefPubMed

Titel: Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985–2016
verfasst von: Satoshi Miyamoto
Katsutsugu Umeda
Mio Kurata
Masakatsu Yanagimachi
Akihiro Iguchi
Yoji Sasahara
Keiko Okada
Takashi Koike
Reo Tanoshima
Masataka Ishimura
Masafumi Yamada
Maho Sato
Yoshiyuki Takahashi
Michiko Kajiwara
Hiroshi Kawaguchi
Masami Inoue
Yoshiko Hashii
Hiromasa Yabe
Koji Kato
Yoshiko Atsuta
Kohsuke Imai
Tomohiro Morio
Publikationsdatum: 04.01.2022
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 3/2022
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-021-01199-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985–2016

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

A Pitfall of Whole Exome Sequencing: Variants in the 5′UTR Splice Site of BTK Causing XLA

Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome

Identification of Germline Non-coding Deletions in XIAP Gene Causing XIAP Deficiency Reveals a Key Promoter Sequence

Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients

Clinicopathological Manifestations and Immune Phenotypes in Adult-Onset Immunodeficiency with Anti-interferon-γ Autoantibodies

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin